Breast cancer is the most treatable cancer, yet it remains the leading cause of death by cancer in women—largely because national screening programs miss up to 1 in 3 cases. The problem is even worse for women with dense breasts, who make up 50% of the screening population and for whom mammography is less reliable. At The Blue Box, we've developed a urine-based breast cancer test with a sensitivity of 88.42%, outperforming mammography by 15% overall—and by 30% in women with dense breasts. We're launching clinical trials in 2025 and bringing our test to gynecology clinics by 2026.